Neil Cohen - Mar 14, 2022 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Neil Cohen
Stock symbol
CMMB
Transactions as of
Mar 14, 2022
Transactions value $
$26,120
Form type
4
Date filed
3/15/2022, 04:07 PM
Previous filing
Mar 9, 2022
Next filing
May 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMMB American Depositary Shares Purchase $8.4K +2K +45.36% $4.20 6.41K Mar 14, 2022 Direct F1, F2
transaction CMMB American Depositary Shares Purchase $8.6K +2K +31.21% $4.30 8.41K Mar 14, 2022 Direct F1, F2
transaction CMMB American Depositary Shares Purchase $9.12K +2K +23.78% $4.56 10.4K Mar 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6.82K $0.00 6.82K Mar 7, 2022 American Depositary Shares 6.82K $3.53 Direct F1, F3, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11.9K $0.00 11.9K Apr 19, 2021 American Depositary Shares 11.9K $27.26 Direct F1, F3, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +688 $0.00 688 Mar 16, 2021 American Depositary Shares 688 $13.17 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
F3 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4 These options vest and become exercisable in their entirety on March 16, 2023 subject to the Reporting Person's continued service.
F5 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F6 These options vest and become exercisable as follows: 1/3 vest on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.